Management ChangeJul 6, 2026, 03:01 PM
AbCellera Appoints Dr. Lynn Seely to Board of Directors
AI Summary
AbCellera Biologics Inc. announced the appointment of Lynn Seely, M.D. to its Board of Directors as a new independent Class III director. Dr. Seely will serve until the 2029 annual meeting and will be compensated under the Non-Employee Director Compensation Policy. Her extensive background includes leadership roles at Lyell Immunopharma, Myovant Sciences, and Medivation, bringing significant experience in biopharmaceutical development and commercialization to AbCellera's board.
Key Highlights
- AbCellera appointed Lynn Seely, M.D. as a new Class III director to its Board of Directors.
- Dr. Seely will serve until the Company's 2029 annual meeting of shareholders.
- The Board determined Dr. Seely is independent under NASDAQ rules and Company guidelines.
- She will participate in the Company's Non-Employee Director Compensation Policy.
- Dr. Seely is currently President and CEO of Lyell Immunopharma Inc.
- She previously served as President, CEO, and board member of Myovant Sciences Inc.
- Dr. Seely also led clinical development at Medivation Inc., including the oncology drug Xtandi®.
Price Impact
More from ABCL